Nov.02 -- Vanita Gupta, president and chief executive officer at the Leadership Conference on Civil Rights, discusses what social media platforms have done to safeguard the election. Gupta spoke Oct. 30 with Bloomberg's Emily Chang.
Nov.02 -- Vanita Gupta, president and chief executive officer at the Leadership Conference on Civil Rights, discusses what social media platforms have done to safeguard the election. Gupta spoke Oct. 30 with Bloomberg's Emily Chang.
Following the wild ride that was 2020, where does the market go from here? Major strides have been made in the COVID-19 vaccine race, yet the near-term picture remains unclear, blurred by the virus’ resurgence and the stimulus stalemate on Capitol Hill.In times like these, the investing greats can serve as a source of inspiration, namely billionaire Israel “Izzy” Englander.Who exactly is Englander? The legend, who started trading stocks when he was in high school, began his career interning at investment firm Oppenheimer, later going on to purchase a seat on the American Stock Exchange, where he would serve as a floor broker, trader and specialist.In 1989, along with Ronald Shear, Englander founded hedge fund Millennium Management. As evidence of his stellar track record, the guru took the $35 million the fund was started with and turned it into over $40 billion in assets under management. With his personal net worth clocking in at $7.2 billion, it’s no wonder Wall Street pays attention when Englander makes a move.Bearing this in mind, our focus shifted to Millenium’s most recent 13F filing, which discloses the stocks the fund snapped up in the third quarter. Locking in on two tickers in particular, TipRanks’ database revealed that both names score a “Strong Buy” analyst consensus. What’s more, the analyst community sees massive upside potential in store for each.G1 Therapeutics (GTHX)Bringing a deep understanding of the biology of cancer and extensive drug discovery experience to the table, G1 Therapeutics works to develop therapies that could potentially improve the lives of patients battling the deadly disease. Ahead of a key regulatory decision, the Street is pounding the table on this name.During the third quarter, Englander and Millennium picked up a new stake in GTHX. Pulling the trigger on 555,937 shares, the value of the holding comes in at $6,421,000.Turning to the analyst community, Needham’s Chad Messer tells clients that he has high hopes ahead of the February 15 PDUFA date for trilaciclib, its therapy designed to improve outcomes for cancer patients treated with chemotherapy. The therapy’s NDA was accepted in August for Priority Review based on results from three randomized clinical studies in small cell lung cancer (SCLC), with the FDA indicating that it doesn’t plan on holding an advisory committee (AdComm) meeting.As trilaciclib is the first CDK4/6 inhibitor to be used to treat chemo-induced bone marrow toxicity, Messer argues that the lack of an AdComm is “meaningful.” Expounding on this, he stated, “We believe this reflects the agency's appreciation of the unmet need, comfort with the safety profile of the CDK4/6 class, and efficacy profile of trilaciclib.”GTHX will also focus on the inclusion of trilaciclib into NCCN guidelines. It should also be noted that a Phase 3 pivotal study evaluating the candidate in metastatic colorectal cancer (mCRC) is set to kick off by year end.Adding to the good news, GTHX and its partner, Boehringer Ingelheim, are preparing for the commercial launch of trilaciclib, with the companies covering approximately 2,500 treating oncologists and providing educational materials regarding the use of trilaciclib ahead of treatment and the benefits of multi-lineage preservation.If that wasn’t enough, the rintodestrant (its selective estrogen receptor degrader (SERD) in development for the treatment of estrogen receptor-positive (ER+) breast cancer) plus palbociclib combination study was able to wrap up enrollment earlier than expected, reflecting “the appeal of an all-oral treatment regimen during a global pandemic,” in Messer’s opinion. With a data readout slated for Q2 2021, the analyst believes a “positive readout could prove to be a significant value driver.”In line with his optimistic approach, Messer reiterated a Buy rating and $74 price target, indicating 417% upside potential. (To watch Messer’s track record, click here)Are other analysts in agreement? They are. Only Buy ratings, 3 to be exact, have been issued in the last three months. Therefore, the message is clear: GTHX is a Strong Buy. Given the $59 average price target, shares could rise 312% in the next year. (See GTHX stock analysis on TipRanks)Epizyme (EPZM)Also fighting the good fight against cancer, as well as against other serious diseases, Epizyme wants to find new treatments through novel epigenetic medicines. Even though the company faces headwinds with regard to its recent product launch, several members of the Street believe big things are in store.Millenium purchased 461,258 shares during the third quarter, with the buy reflecting a new position for the hedge fund. As for the value of the holding, it lands at $5,503,000.Writing for Wedbush, 5-star analyst David Nierengarten points out that the pandemic has limited oncologist visits, and therefore, Tazverik (the company's follicular lymphoma treatment) sales were lower than he expected. He points out that “the pandemic shifts the launch curve to an ‘incidence model’ rather than a prevalence model, as there is a limited patient pool to draw from if they are delaying office visits,” with patients waiting to seek treatment until they experience symptoms of progression.Additionally, although the launch is virtual and physician awareness is high, physicians are opposed to prescribing a new medication without examining the patient in person. That being said, Nierengarten remains optimistic about the therapy.“Despite these headwinds, Tazverik came close to meeting our estimates, and it is gaining market share, including seeing initial sales in second line. We expect more meaningful second line sales to begin in 2021, and have more gradually incorporated them into our launch curve,” the analyst explained.When it comes to the time on therapy, Nierengarten argues it’s too early to come to any conclusions. However, he highlights the fact that durability of response was relatively long and patients were treated past progression in the registration study. “Furthermore, the headwind against switching therapies turns into a tailwind of Tazverik maintenance once a patient is on therapy. This will likely contribute more meaningfully to 2H21 revenues and potential revenue outperformance,” he added.Summing it all up, Nierengarten commented, “At current levels, we believe investors are too negative on Tazverik’s potential and patience should be rewarded.”Based on all of the above, Nierengarten sides with the bulls, reiterating an Outperform rating and $27 price target. This target conveys his confidence in EPZM’s ability to climb 122% higher in the next year. (To watch Nierengarten’s track record, click here)Most other analysts echo Nierengarten’s sentiment. 3 Buys and 1 Hold add up to a Strong Buy consensus rating. With an average price target of $23.25, the upside potential comes in at 91%. (See EPZM stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
The year is coming to an end, and bullish news is mounting for the energy industry, presenting an array of juicy deals to watch this holiday season
I have read a few of your HelpMeRetire inquiries, and I have a situation that I can’t seem to find much information about when I read retirement planning guides. I am 60 years old, and my spouse is 45. Our living expenses aren’t extravagant, but we do like to travel.
The stock market is looking robust, but also showing some signs of excessive bullishness. Moderna will seek FDA OK for its coronavirus vaccine. Apple leads four key names to watch.
Wall Street is bracing for Tesla Inc's (NASDAQ: TSLA) arrival to the S&P 500 Index on Dec. 18.What Happened: The addition of the California-based automaker is expected to create challenges because of the company's size, $555 billion, and volatility. Tesla's share price jumped 40% right after the S&P 500 announcement on Nov. 16, and the addition comes at a time of pandemic-related volatility, the Wall Street Journal reports. Tesla is the biggest company to ever join the index, and it'll be the sixth largest by market capitalization. Elon Musk's company might put $100 billion "in motion" when added, as funds try to sell other companies' stock to buy Tesla's, according to WSJ.To help ease the potential trading chaos, some Wall Street managers recommend splitting the addition "over two trading days," something that has never happened before, WSJ notes.Ben Inker, who manages asset allocation at investment manager GMO believes any unpreparedness might have consequences. "The people who will pay the price if S&P screws up are the investors in passive S&P," he says.Why It Matters: Tesla's addition to the S&P 500 also happens the same day the so-called "quadruple witching" takes place. Every last Friday of the quarter marks the day when futures and options expire at the same time, which increases the volume.This, investors say, might help with the liquidity that day but may also increase market volatility. Price Action: Tesla shares traded 0.17% lower at $584.77 in the after-hours markets on Friday.Photo courtesy of UnsplashSee more from Benzinga * Click here for options trades from Benzinga * Guggenheim Fund Mulls Investment in Grayscale Bitcoin Trust * Bloomberg Releases Its 2020 List Of Wealthiest Families In Asia(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
South Korea’s sovereign-wealth fund sold Alibaba, Apple, and Intel stock in the third quarter. It also more than doubled a position in GM stock, a move that is paying off so far in the fourth quarter.
The advancements with COVID-19 vaccines of Pfizer Inc. (NYSE: PFE), Moderna Inc. (NASDAQ: MRNA), and AstraZeneca Inc. (NASDAQ: AZN), along with a resurgence of stock market indices like the Dow Jones Industrial Average and S&P 500, hints at a relatively stable outlook for the next year compared to 2020.Top Wall Street analysts, based on TipRanks ratings, see these four stocks as winning plays as markets brace for the last month of what has been a turbulent year, as first reported by CNBC.Repay Holdings Corp (NASDAQ: RPAY): Last Week, Northland Capital analyst Micheal Grondahl recommended the Atlanta-headquartered payment processing company as a Buy with a price target of $28, a 16.67% upside potential at the time.CNBC cited Grondahl's comments that the company's continued expansion into new key verticals could play an integral role in driving strong financial results -- the auto loan business for used cars as well as the mortgages and refinancing segment backed by the recently-acquired subsidiary Ventanex, for instance.According to TipRanks statistics, Grondahl's calls on Repay have returned profits eight out of 12 times.After a 0.44% dip during Friday's trading hours, RPAY sank 9.17% in the extended trading hours at $21.80.Autodesk Inc (NASDAQ: ADSK): Based on the positive earnings release for the September quarter, Oppenheimer analyst Koji Ikeda recommends Autodesk as a Buy. Ikeda has set a $300 price target with an 11% upside potential on the stock."We believe Autodesk is well-positioned during and post-pandemic to disrupt the future digitization opportunity in the construction and manufacturing industries that should enable the business to achieve its FY2023 financial targets," the Oppenheimer analyst said, as reported by CNBC. According to TipRanks, Ikeda has an over 93% success rate based on 110 ratings, and the calls on Autodesk stock returned profits twelve out of thirteen times.ADSK shares were last seen quoting $273.90, 0.40% higher, at the end of Friday's extended trading session.Anaplan Inc (NYSE: PLAN) With a Buy recommendation and a 21% upside potential, Needham & Company's Scott Berg revised the price target for the cloud-based business planning software company to $85 last week. "[Anaplan] was historically a fairly heavy in-person sale, thus a return to travel/in-person meetings could significantly benefit the company," Berg commented, according to CNBC. Berg added that ongoing partner investments could revive sales once the lockdown measures are scrapped.During Friday after-hours, PLAN stock was seen quoting 1.66% higher at $69.95 per share.Karyopharm Therapeutics Inc (NASDAQ: KPTI) With last week's Buy recommendation for Karyopharm, H.C. Wainwright analyst Edward White set a price target of $41 with a 166.41% upside potential.White relied on Karyopharm's Phase 3 SIENDO study of Xpovio for treating patients with endometrial cancer proceeding as per schedule. Topline estimates of the trials are expected sometime in the second half of next year.White believes that Xpovio sales from dedifferentiated liposarcoma are projected at close to $26 million in 2026, from the estimated $3 million in 2022, CNBC reported.See Also: Wall Street Analysts Say These 5 Stocks Are A Buy As The World Prepares For The Post-COVID-19 EraLatest Ratings for RPAY DateFirmActionFromTo Oct 2020Morgan StanleyInitiates Coverage OnEqual-Weight Sep 2020BarclaysInitiates Coverage OnOverweight Jun 2020Credit SuisseMaintainsOutperform View More Analyst Ratings for RPAY View the Latest Analyst RatingsSee more from Benzinga * Click here for options trades from Benzinga * Airbnb, DoorDash Reportedly Up IPO Valuation Target By B Each * China Tech Companies To Remain 'Very Much A Growth Play' Even Post-COVID-19, Says Credit Suisse(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
President-elect Joe Biden wants to help Americans save for their golden years by expanding access to retirement savings plans, strengthening Social Security, and making health care more affordable.
The so-called “universal charitable deduction” allows non-itemizers to claim a tax break of up to $300 when they file their taxes in 2021. Charitable donations are tax deductible, but taxpayers can only claim the deduction on their federal income taxes if they’re itemize the expenses that are eligible for deductions. Along with charitable donations, these expenses include medical expenses, mortgage interest and state and local taxes (up to $10,000).
Buying a stock is easy, but buying the right stock without a time-tested strategy is incredibly hard. So what are the best stocks to buy now or put on a watchlist?
You can inherit an IRA tax-free, but you could be hit with a 50% penalty if you don't follow the rules for required minimum distributions (RMDs).
A home loan is a powerful financial tool, even if you have the cash to pay outright.
Each week Trifecta Stocks identifies names that look bearish and may present interesting investing opportunities on the short side. Using technical analysis of the charts of those stocks, and, when appropriate, recent actions and grades from TheStreet's Quant Ratings, we zero in on five names. While we will not be weighing in with fundamental analysis, we hope this piece will give investors interested in stocks on the way down a good starting point to do further homework on the names.
Mohamed El-Erian, president of Queens' College University and economic adviser to Allianz, isn't so sure the bull run will last and he explained why in a recent interview.
The investment board of Wisconsin’s state pension sold Bank of America, Wells Fargo, and Exxon stock in the third quarter. It bought JPMorgan stock.
These top sector performers could add to gains into year’s end.
The 90-year-old billionaire is taking advantage of low interest rates. You should, too.
The pandemic has already caused a rise in office vacancies and drop in rents. If enough tenants cancel their leases, delinquencies might also rise.
Does buying gold stocks, or betting on the gold price, make sense, despite vaccine progress and 2020 election results? Here are some things to consider.
In a four-day week where markets were on the rise, cannabis stocks proved to be big winners. Late Friday, stocks surged on news that a federal marijuana legalization bill will get a congressional vote next week.During the holiday week: * The ETFMG Alternative Harvest ETF (NYSE: MJ): gained 12% * The AdvisorShares Pure Cannabis ETF (NYSE: YOLO): was up 15% * The Cannabis ETF (NYSE: THCX): advanced 14.5% * The Amplify Seymour Cannabis ETF (NYSE: CNBS): rose 14% * The SPDR S&P 500 ETF Trust (NYSE: SPY) was up 1.5%.In other news, music industry mogul Jay-Z announced he is set to join a newly formed cannabis company that's expected to become the largest in California.The venture was formed via a partnership between Caliva, Left Coast Ventures, Subversive Capital Acquisition Corp. (OTCQX: SBVCF) and Roc Nation, the entertainment company Jay-Z launched in 2008.Jay-Z will take on the title of "Chief Visionary Officer." The transaction is slated to close in January 2021 with Steve Allan as CEO.In his role, Sean Carter (Jay-Z) is expected to help oversee a corporate venture fund focused on social equity measures. The fund will aim at an initial funding target of $10 million and commit to contributing at least 2% of its net income to invest in minority-owned cannabis businesses and donate to organizations seeking to rectify the wrongs of prohibition.Meanwhile, Detroit approved an ordinance that green-lights the licensing process for adult-use marijuana businesses. The Detroit City Council voted unanimously to begin granting licenses to adult-use retailer establishments, growers, processors, safety compliance facilities, temporary marihuana events, microbusinesses, consumption lounges and transporters.The ordinance includes measures to benefit "Legacy Detroiters" and people with prior marijuana convictions. Via a social equity program included in the ordinance, 50% of all licenses will be granted to Detroit Legacy applicants.Earnings Reports Cansortium Inc. (CSE: TIUM) (OTCQB: CNTMF) reported revenue of $14.3 million for the third quarter of this fiscal year. That's a year-over-year increase of 94%.Jushi Holdings Inc. (CSE: JUSH) (OTCQB: JUSHF) said its third-quarter revenue totaled $24.9 million, up by 67% over the quarter. The revenue increase could be attributed to the revenue growth at its BEYOND/HELLO stores in Illinois and Pennsylvania, as well as Nevada operations.Moreover, the revenue increased by approximately 45% on a same-store basis compared to the previous quarter, excluding the two Philadelphia-based stores temporarily closed since June due to George Floyd-related protests.Earlier in the week, the company announced it will almost double the amount of square footage of its subsidiary's grower-processor facility in Scranton, Pennsylvania. The expansion is expected to create more than 100 new jobs in the area.Vireo Health International Inc. (CSE: VREO) (OTCQX: VREOF) revealed third-quarter revenue of $13.4 million. That's up by 68% year-over-year. The physician-led cannabis company generated revenue in seven states during the third quarter: New Mexico, Minnesota, Ohio, New York, Maryland, Pennsylvania and Arizona.Its quarterly adjusted EBITDA was a loss of $675,808, which stands against a loss of $5.2 million in the same quarter of the prior year.Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) saw a 219% spike in net revenue (CA$3.2 million) for the third quarter compared to the previous three-month period. This was due to greater sales volume via direct sales to provincial suppliers and under the Agro-Greens Agreement.Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) saw a 219% spike in net revenue (CA$3.2 million) for the third quarter compared to the previous three-month period. This was due to greater sales volume via direct sales to provincial suppliers and under the Agro-Greens Agreement.Planet 13 Holdings Inc. (CSE: PLTH) (OTCQX: PLNHF) announced third-quarter revenues of $22.8 million, up by 36.5% from $16.7 million in the corresponding quarter of 2019.View more earnings on MJAdjusted EBITDA of $6.2 million compared to $3.4 million in the third quarter of the prior year.San Diego-based Driven Deliveries Inc. (OTCQB: DRVD) announced Wednesday that gross revenue for the third quarter, as of Sept. 30, totaled record sales of $7.2 million. Net Revenue for the same period was $6 million -- a 393% year-over-year increase.Decibel Cannabis Company Inc. (TSXV: DB) (OTCQB: DBCCF) reported third quarter results including: * Total net revenue growth of 29% over the second quarter to $7.6 million * Net revenue growth of 163% over the comparative 2019 period * Positive adjusted EBITDA for the first time * The opening of two new Alberta retail stores in July * Completion of a large scale, indoor cultivation facility -- Thunderchild Cultivation -- in July.Cannabis and hemp-CBD company Pure Harvest Corporate Group Inc. (OTCQB: PHCG) unveiled an increase in revenue via its most recent quarterly report.Highlights include: * Q3 2020 revenues increased by 8,066% ($318,690) from Q2 2020 Revenue ($3,951) * Gross profit went from being in the red back in Q2 2020 to the black, now hovering $258,138 * The company's recently opened dispensary located in Dumont-Downieville, Colorado has experienced month-after-month growth -- including a 15% increase in sales in the month of October.Read all about these earnings reports and others in Benzinga Cannabis' Earnings Center.More News From The Week A Change.org petition asking New Jersey Governor Phil Murphy to free prisoners charged with marijuana possession has gained steam after New Jersey voters overwhelmingly approved a constitutional amendment to legalize recreational marijuana earlier this month. Marquel Williams, the man who started the petition, hopes that releasing these prisoners will help to slow the spread of COVID-19, which has already devastated New Jersey's prisons. "This is the kind of no-nonsense campaign we should all be able to get behind. New Jersey voters made it clear at the ballot box this November that they support legalizing cannabis possession, cultivation and retail. Why are we leaving folks in prison behind, when their crimes are no longer illegal and a pandemic is raging unchecked through our prison system? We have the rare opportunity to provide solutions and hope in a year that's mostly taken that away from us. I want people to get in the mindset of actively creating changing and normalizing justice being the only option," Williams told Benzinga.Australian cannabis company Cann Group Limited (ASX: CANN) (OTC: CNGGF) revealed Monday it has obtained credit approval from National Australia Bank (NAB) for its $50 million secured debt facility.TerrAscend Corp. (CSE: TER) (OTCQX: TRSSF) began serving medical marijuana patients in the Apothecarium Phillipsburg after obtaining the last needed authorization from the NJ Department of Health to distribute medical cannabis from its New Jersey dispensary.Auxly Cannabis Group Inc. (TSXV: XLY) (OTCQX: CBWTF) secured $12 million in financing. The Toronto-based company confirmed Tuesday it has upsized the previously announced bought-deal offering of its units to 40 million units at 30 cents per unit.Women-centric cannabis brand Her Highness said it is expanding into Nevada through a production licensing partnership with MSO Body and Mind Inc. (CSE: BAMM).Benzinga Cannabis' content is now available in Spanish on El Planteo.Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB) agreed to provide Israel-based Cantek Holdings with at least 4,000 kilograms of bulk dried flower yearly.Greenlane Holdings Inc (NASDAQ: GNLN) announced a retail partnership with Stundenglass, which will bring the Gravity Hookah to consumers and wholesale purchasers in the U.S., Canada, and the EU. The Gravity Hookah is a gravity-powered, contactless water pipe that can accommodate hookah, dry herb, and concentrate consumptions. The product features an innovative 360-degree gravity system that utilizes kinetic motion activation, cascading water, and opposing airflow technology to produce clean and flavorful hits."The Greenlane team is honored to partner with Stundenglass and introduce the Gravity Hookah to our loyal customers, providing them with a truly unique and revolutionary consumption experience." Aaron LoCascio, Co-Founder and Chief Executive Officer of Greenlane Holdings.MedMen Enterprises Inc. (CSE: MMEN) (OTCQX: MMNFF) teamed up with Al Harrington's Viola. The multi-state cannabis retailer will start offering Viola products in all of its California-based stores. The offering will include five cannabis flower strains, and one pre-roll option.Cannabis-focused media and tech company Weedmaps will be an official sponsor of the Mike Tyson/Roy Jones Jr. fight taking place on Nov. 28 at 8 p.m. EST.Through a partnership with viral entertainment platform Triller, Weedmaps branding will be present on the broadcast, as well as on the actual ring, the locker room and the press room.Top Stories Of The Week Check out the top stories on Benzinga Cannabis this week: * A Weed-Infused Cooking Class For Thanksgiving? One Cannabis ETF's Unique Marketing Strategy * Glass House Shows Us Its Massive Cannabis Greenhouse * Tyson Hypes Smart Cups Ahead Of Jones Fight, Tells Benzinga It's 'Disrupting Beverage Industry' * Jerry Garcia Cannabis Brand To Hit California Shelves This Month * New Cannabis Products: Live Resin Edibles, Infused Olive Oil, High Dose CBD Beverages * New Cannabis Products: A Non-Profit Brand For Justice, New Issue Of DoubleBlind Mag, CBD Consumables * Viridian Chart Of The Week: Cannabis Debt Financing Is Booming Across The U.S. * 'CBD Is Not A Narcotic': European Court Rules Against Restrictions On CBD Commerce * THCV: The Rare Cannabinoid That'll Conquer The Industry * Mexico's Cannabis Legalization Bill Will Boost Business, But There Are ConcernsTop Spanish stories: * Mexico: Preocupaciones por la Legalizacion de la Marihuana * ¿Ayudara este Cannabinoide Sintetico a Pacientes de Cancer a Recuperar el Apetito? * Porros, Viajes y Buen Contenido: Conoce a En Vola, la Plataforma Cannabica Chilena * ¿Marihuana o Cannabis?: un Vistazo a las Palabras y Frases Polemicas de la Industria * Como Hacer Hachis o Hash: Instrucciones Paso a Paso * Pandemia y Discord: Presente y Futuro de las Mujeres en el Freestyle * Las Mejores Cepas de Marihuana de Todos los Tiempos, segun Expertos * Mescalina: Todo lo que Siempre Quisiste Saber y Nunca te Animaste a Preguntar * Donde Comer Ramen en Buenos Aires * Facu Banzas: Stream, Porro y Amor por el Counter Strike * ¿Warren Buffett Invirtio en Tesla? ¿Por Que Se Especula? * Ayahuasca: Todo lo que Necesitas SaberLead image by Ilona Szentivanyi. Copyright: Benzinga.See more from Benzinga * Click here for options trades from Benzinga * A Weed-Infused Cooking Class For Thanksgiving? One Cannabis ETF's Unique Marketing Strategy * The Week In Cannabis: Stocks Outperform S&P, Mexico Moves Forward, Earnings, And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.